Ticker brief

NGNE

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
10
authors 14d
7

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-06-22 → 2026-07-02 · now +0.00 (−1 bearish … +1 bullish)
Who spoke7
authorgradetrader scoresignalsmean sent
@Quantumup1C-1.953+0.00
@Brad_E_SchulzC·2+0.28
@semodoughC-0.751+0.45
@OzmosiHealthC·1+0.50
@BioStocksC-0.391-0.15
@BiopharmIQB·1-0.05
@MinervaCapC-1.281+0.00
Recent signals10of 10 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-07-02@Quantumup1+0.00Citizens reiterated TSHA Market Outperform-$11 after positive meeting readout.·
2026-07-01@MinervaCap+0.00Watchlist for tomorrow without explicit trade intent.·
2026-07-01@Brad_E_Schulz+0.30Lists stocks up at least 4% on at least 1.5x average volume.·
2026-07-01@BiopharmIQ-0.05Biotech open news list with percentage moves and named catalysts.·
2026-07-01@Brad_E_Schulz+0.25Intraday stocks up at least 4% on at least 1.5x average volume.·
2026-07-01@BioStocks-0.15NGNE $125M offering priced at $30 per share.·
2026-06-29@OzmosiHealth+0.50Neurogene reports positive long-term Phase 1/2 clinical data for Rett Syndrome gene therapy.·
2026-06-26@Quantumup1+0.00Mizuho reiterated ACAD Outperform with $35 target after CHMP positive opinion.·
2026-06-22@Quantumup1+0.00BofA reiterates TSHA Buy and raises PO to $10 after REVEAL data.·
2026-06-22@semodough+0.45LifeSci rates NGNE Outperform with $60 PT and says TSHA-102 update validates thesis.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.